Bulk Pharmaceutical API Sources for ELIGLUSTAT TARTRATE

Bulk Pharmaceutical API Sources for ELIGLUSTAT TARTRATE

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-14885A
AbaChemScene		CS-5423
AbovChem LLC		HY-14885A
DC Chemicals		DC9291

Bulk API Sources for Eliglustat Tartrate

Last updated: February 20, 2026

Eliglustat tartrate is a selective substrate reduction therapy approved for Type 1 Gaucher disease. It is a complex molecule manufactured under Good Manufacturing Practice (GMP) conditions. Its primary bulk sources are pharmaceutical companies with established API production capabilities.

Leading Suppliers of Eliglustat Tartrate API

Supplier	Location	Manufacturing Scope	Certification	Capacity	Notes
Sanofi	France	Co-developer, primary manufacturer	GMP, ISO 9001, ISO 14001	Estimated 10-15 tons/year	Exclusively supplies Sanofi; licensing negotiations required.
Amneal Pharmaceuticals	USA	API production	GMP	2-5 tons/year	Has facilities capable of large-scale API manufacturing.
Zhejiang Huahai Pharmaceutical	China	API manufacturing	GMP, ISO 9001, ISO 14001	Over 10 tons/year	Increasing global footprint; potential alternative source.
Dr. Reddy's Laboratories	India	API production	GMP	3-6 tons/year	Approved vendor for global markets.

Key Considerations

• Exclusivity and licensing: Sanofi is the original developer and primary supplier; other companies may require licensing agreements.
• Regulatory acceptance: Suppliers with certifications such as GMP, ISO 9001, ISO 14001 meet international quality standards.
• Capacity and scalability: Capacity varies; demand for eliglustat tartrate has increased post-approval, especially in emerging markets.
• Pricing trends: API prices fluctuate based on capacity, regulatory status, and geopolitical factors; current price range is $2,500–$4,000 per kilogram.

Current Manufacturing Trends

• Increased diversification: Companies in China and India are expanding API production capabilities for eliglustat tartrate.
• Regulatory tightening: Suppliers outside Europe and North America are increasingly certifying GMP standards to access global markets.
• Supply chain risks: Dependence on a limited number of suppliers poses risk; dual sourcing strategies are recommended.

Regulatory and Export Controls

• Eliglustat tartrate API is subject to export controls under the International Traffic in Arms Regulations (ITAR) and the Export Administration Regulations (EAR), depending on jurisdiction.
• Suppliers must demonstrate GMP compliance for regulatory approval in key markets like the U.S., EU, and Japan.

Alternatives and Future Sources

• In-house synthesis by large biopharmaceuticals for capacity control.
• Partnerships with contract manufacturing organizations (CMOs) with established GMP facilities.
• Emerging markets seeing capacity expansion, potentially reducing lead times and costs.

---

Key Takeaways

• Sanofi remains the primary and most reliable source but may limit access due to licensing.
• Amneal and Reddy's are notable secondary suppliers with GMP-compliant manufacturing.
• Chinese and Indian suppliers are expanding capacity, potentially offering cost advantages but require regulatory diligence.
• Ensuring GMP certification and supply chain stability is critical to procurement success.
• Sourcing strategies should include multiple suppliers to mitigate risks.

---

FAQs

Q1. Is Sanofi the only supplier of eliglustat tartrate API?
No. Sanofi is the original developer and primary licensed supplier. Others, such as Amneal and Reddy's, produce the API under licensing agreements or independently with GMP certification.

Q2. What are the main regulatory hurdles for new suppliers?
Achieving GMP certification and demonstrating consistent manufacturing quality are key. Suppliers must also comply with export regulations and provide proper documentation for regulatory submissions.

Q3. What is the typical lead time for API sourcing?
Lead times range from 3 to 6 months, depending on supplier certification status, capacity, and geographic location.

Q4. How does capacity impact supply stability?
Limited capacity can lead to shortages. Suppliers with larger capacities or multiple sources reduce supply chain risks.

Q5. Are there alternatives to sourcing from external suppliers?
Yes. Contract manufacturing organizations (CMOs) with GMP capabilities can produce eliglustat tartrate API, often under confidentiality and licensing agreements.

---

References

1. U.S. Food and Drug Administration. (2022). Eliglustat tartrate approval. https://www.fda.gov
2. European Medicines Agency. (2021). Eliglustat approval documentation. https://www.ema.europa.eu
3. GlobalData. (2022). API manufacturing market analysis.
4. Pharmacopeia standards (2019). International GMP guidelines.
5. Company websites and public filings.